An attempt was made to prepare FITC-labeled-lactoferrin (LF-FTC)-loaded microparticles, durable under gastrointestinal conditions,ˆrst by the combination of alginate/calcium complexation and emulsiˆcation-evaporation and next by treatment with chitosan solution. The obtained microparticles were examined for particle characteristics, in vitro release proˆles and physical stability in solutions of pH 1.2 and 6.8. The obtained chitosan-coated alginate/calcium complex microparticles (Ch/Al/Ca-MP) showed almost uniform size of 1 2 mm and a spherical shape with a nonsmooth surface. The content and recovery of LF-FTC in Ch/Al/Ca-MP fell as the concentration of chitosan solution used in chitosan coating increased. The release rate of LF-FTC was faster in Ch/Al/Ca-MP prepared with more chitosan at pH 1.2 and 6.8. Ch/Al/Ca-MP coated with 0.25 and 0.5％ (w/v) chitosan solution showed good gradual release characteristics in vitro. Furthermore, they were durable at pH 1.2 and 6.8, though swelling and softening of the microparticles occurred at pH 6.8. It is suggested that alginate/calcium complex microparticles coated with 0.25 0.5％ (w/v) chitosan solution would be useful for the intestinal delivery of LF.
INTRODUCTION
Lactoferrin (LF) is an iron-binding glycoprotein, expressed abundantly in milk, saliva, tears, other exocrine secretions, and polymorphonuclear leukocyte granules. 1 3) It has attracted much attention in thê eld of alternative medicine, because it exhibits various biological functions, including antibacterial, antiviral, antitumor, antiin‰ammatory and immunomodulatory eŠects. 4 9) Generally, many developed drugs can cause toxic side eŠects as well as having therapeutic e‹cacy, resulting in their limited use. On the other hand, since LF has no toxic side eŠects, it is expected to be a possibly useful therapeutic agent for host defense and the treatment of various refractory diseases. LF can act directly in diseased areas, and its minimal inhibitory concentrations (MICs) for bacteriostatic and / or bactericidal activities were reported. 10, 11) In addition, LF shows eŠectiveness against diseases developing in the remote sites via LF receptor-mediated and immune defense systems etc. 8,9,12 14) For instance, oral administration of LF exhibits good eŠect against oral candidiasis and urinary tract infection or tumor. 15 17) However, for oral administration of LF, its degradation by peptic enzymes is a problem. Therefore, dosage forms to allow LF to reach target sites eŠectively are important to improve its e‹cacy. It was recently reported that oral pretreatment using LF-containing liposomes was more eŠective than that with LF alone for anti-in‰ammatory eŠects. 9) Also, enteric coating is eŠective for protection from peptic degradation and intestinal absorption. 18) Polymeric microparticles are considered to be eŠective to protect LF under stomach conditions, and are expected to enhance mucosal adhesion and penetration into the mucus layer. 19) Previously, we prepared chitosan microparticles loaded with LF, and characterized their in vitro properties. 20) Simple chitosan microparticles exhibited better particle characteristics and release proˆle than the microparticles prepared by sonication or by complexation with sulfate ions. However, such chitosan microparticles were considered to be problematic because they could dissolve, swell and degrade physically in gastric pH. 21) Therefore, in this study, we attempted to prepare chitosan-coated alginate/calcium complex microparticles in order to obtain microparticulate formulations of LF, which is physically durable in the stomach and intestine. Chitosan/alginate/ calcium complex microparticles are known to be able to be produced by several methods. 22 25) Wittayaareekul et al. reported the two-step preparative method in which alginate-calcium complex wasˆrst produced and subsequently complex microparticles were further coated with chitosan by soaking in chitosan solution. 23) However, they were much larger than 1 mm or less in particle size, which is appropriate for longer mucoadhesion, or were not uniform. In the study, the preparation of smaller microparticles of around 1 mm in size was attempted by a combination of chitosan-alginate-calcium complexation and emulsiˆcation-evaporation technique. The obtained microparticles were examined for particle characteristics, in vitro release and physical states in JP15 1st and 2nd ‰uids.
MATERIALS AND METHODS

Chemicals
Bovine lactoferrin (LF) was donated by NRL Pharma Inc. (Kawasaki, Japan). Sodium alginate (Al Na; 80 120 cP) and calcium chloride were purchased from Wako Pure Chemicals Industries, Ltd. (Osaka, Japan). Daichitosan VL (81％ deacetylation degree and extra low viscosity grade) was supplied by Dainichiseika Color & Chemicals Mfg. Co., Ltd. (Tokyo, Japan), and used as chitosan (Ch) throughout the experiment. Sorbitan sesquioleate (SO-15) was obtained from Nikko Chemicals Co., Ltd. (Tokyo, Japan). All other chemicals were of reagent grade.
Preparation of Microparticles First, LF was labeled with ‰uorescein isothiocyanate (FITC). LF (100 mg) and FITC (10 mg) were dissolved in 10 ml of 0.1 M carbonate buŠer, pH 8.4, and stirred for 4 h. The mixture underwent gel-ˆltration using a Sephadex 50 column, dialyzed against water and lyophilized, resulting in 81 mg of FITC-labeled LF ( LF-FTC ) , which displayed the absorbance coe‹cient, E (1％ (w/v), 1 cm), of 44.5 in JP15 2nd ‰uid.
Ten milliliters of aqueous solution containing AlNa (150 mg) and 5 ml of aqueous solution containing LF-FTC (18 mg) were mixed, and added to 300 ml of liquid para‹n containing 1％ (w/v) SO-15. The mixture was stirred at 1000 rpm for 1 h. Then, 3 ml of aqueous solution containing 300 mg of CaCl 2 were added, and stirring was continued under the same conditions for 15 min. The mixture underwent reduced pressure using a rotary evaporator under gentle stirring. After complete evaporation of water, n-hexane (300 ml) was added to the mixture, and stirred. The mixture was centrifuged to obtain microparticles named Al/Ca-MP.
Al/Ca-MP (50 mg) were added to 0.25, 0.5 or 1％
(w/v) chitosan solution in 1％ (v/v) aqueous acetic acid solution (20 ml), and stirred at 500 rpm for 1 h. The residue was washed twice with 20 ml of water. Theˆnal residue was obtained as chitosan-coated Al/ Ca-MP, named Ch/Al/Ca-MP. Measurement of Particle Characteristics Drug content was measured as follows. A certain amount of Al/Ca-MP was suspended in a certain volume of JP15 1st ‰uid, and stirred vigorously. After the mixture was centrifuged, the clear supernatant and solid portion were separated. The solid residue was dissolved by stirring in a certain volume of JP15 2nd ‰uid. The above clear supernatant in JP15 1st ‰uid and the solution in JP15 2nd ‰uid were examined spectrophotometrically at 446 nm and 494 nm, respectively, to determine the concentration of LF-FTC in both media, leading to the LF-FTC content in Al/Ca-MP.
In the preparation of Ch/Al/Ca-MP, the clear supernatants obtained by treatment with chitosan solution and after washing with water were examined spectrophotometrically to determine LF-FTC concentration in the media. The LF-FTC content in Ch/Al/ Ca-MP was calculated by subtracting the amount in the media from that in the initial amount in Al/Ca-MP.
The microparticles were observed by scanning electron microscopy (SEM) using a JEOL JSM-5600LV scanning electron microscope (JEOL, Tokyo, Japan) after coating at approximately 10 nm in thickness with platinum. Their particle size and shape were investigated using SEM images. Parallel lines touching the opposite sides of each microparticle were made in the same direction, and the distance between parallel lines, called Green diameter, was measured. The Green diameter corresponds to the Feret diameter used by the Association of Powder Process Industry and Engineering, Japan. The measurement was performed for 150 microparticles chosen at random.
In Vitro Release Studies Ch/Al/Ca-MP were suspended in JP15 1st and 2nd ‰uids at a concentration of 0.6 mg/ml, and shaken horizontally at 100 strokes per min at 37°C. At appropriate time points, the whole sample was centrifuged at 3000 rpm for 10 min, and the supernatant was measured spec- trophotometrically to determine the LF-FTC concentration. After the measurement, the whole supernatant and the residue were mixed, and the incubation was re-started under the same condition. The release amount was calculated from the concentration of LF-FTC. The incubation time was deˆned as the time for the sample to be set in the thermostat bath at 37°C. In addition, the sequential release test was conducted for Ch/Al/Ca-MP. Namely, Ch/Al/Ca-MP were suspended in JP15 1st ‰uid at a concentration of 0.6 mg/ml at 100 strokes per min at 37°C for 1 h. The whole sample was centrifuged at 3000 rpm for 10 min, and the supernatant was analyzed spectrophotometrically to determine the released LF-FTC. The residue was then suspended in the same volume of JP15 2nd ‰uid, and the release test was continued for another 4 h. The release amount was determined in the same manner as above.
Physical States of Microparticles in Media at DiŠerent pHs
Ch/Al/Ca-MP prepared at a chitosan concentration of 0.5％ (w/v), named Ch0.5/Al/ Ca-MP, were suspended in JP15 1st and 2nd ‰uids, and incubated at a concentration of 0.6 mg/ml at 100 strokes per min at 37°C for 3 h. The suspensions were then observed visually and using an optical microscope and a ‰uorescence microscope to investigate their physical particle states. In addition, Ch0.5/Al/ Ca-MP were examined for their particle states in sequential incubation using JP15 1st ‰uid for initial 3 h and JP15 2nd ‰uid for another 3 h, with incubation conditions in the same as above. After incubation in JP15 1st ‰uid and next in JP 2nd ‰uid, the suspension was observed visually and by optical and ‰uorescence microscopy.
Moreover, after the sequential release test stated above, the residue obtained by centrifugation of the incubated suspension was dried in a desiccator, and the dried sample was observed by SEM.
RESULTS AND DISCUSSION
Particle Characteristics
When Al/Ca-MP were prepared by the emulsiˆcation-evaporation method under the present conditions, their yield, drug content and size of Al/Ca-MP were obtained as shown in Table 1 . Al/Ca-MP released LF-FTC in JP15 1st ‰uid to a fair extent. The Al/Ca-MP suspension in JP15 1st ‰uid was centrifuged, and the resultant precipitate dissolved easily in JP15 2nd ‰uid. These dissolution properties allowed measurement of the LF-FTC content in Al/Ca-MP. The used materials, including LF-FTC, were recovered in Al/Ca-MP at a high recovery ratio. As the used materials were watersoluble but hardly soluble in organic solvent, most of them were considered to be recovered in the microparticles, Al/Ca-MP. Al/Ca-MP were approximately spherical and their size was mainly in the range of 1 2 mm, with a mean diameter of 1.45 mm (Fig. 1) . Three kinds of Ch/Al/Ca-MP were prepared using 0.25, 0.5 and 1.0％ (w/v) chitosan solution in 1％ (v/ v) acetic acid as the solution for chitosan coating, and they were named Ch0.25/Al/Ca-MP, Ch0.5/Al/Ca-MP and Ch1.0/Al/Ca-MP, respectively. Their yields, drug contents and sizes are summarized in Table 2 . Ch/Al/Ca-MP hardly dissolved in aqueous media, including JP15 1st and 2nd ‰uids. Therefore, the content of LF-FTC was determined by subtracting the washed-out amount of LF-FTC from the initial amount of loaded LF-FTC. The amount of the obtained Ch/Al/Ca-MP was considerably less than that of the starting Al/Ca-MP. This was probably because Ca ion (CaCl 2 ), not associated with complexation, was washed out during the treatment with chitosan solution. As the chitosan concentration increased, the amount of obtained Ch/Al/Ca-MP tended to increase, which was probably because more complexation between alginate and chitosan should be formed with the increase in chitosan concentration. On the other hand, the content of LF-FLC in Ch/Al/Ca-MP decreased with the increase in chitosan concentration. Also, a recovery ratio of LF-FTC became lower by the treatment with chitosan solution of higher concentration. Addition of chitosan solution was considered to create the complex of chitosan and alginate and to cause some LF-FTC to be removed out because of the competition with chitosan for the complex formation with alginate. Therefore, more LF-FTC was considered to be lost with the chitosan solution of higher concentration. The mean particle size was 1.1 1.3 mm in all Ch/Al/Ca-MP, and the particle size range was from 0.8 mm to 1.5 mm. Furthermore, Ch0.25/Al/Ca-MP obviously exhibited rough surface (Fig. 1) . Also, the other Ch/Al/Ca-MP seemed not to be completely spherical, though they were not observed clearly as compared with the surface of Ch0.25/ Al/Ca-MP. As the surplus CaCl 2 , not associated with complexation, was removed out in treatment with chitosan solution, which might make the surface rough. Chitosan-alginate complexation might cause the recovery of the smooth surface from the roughness. However, as the details were not grasped from Fig. 1 , further examination, especially that of the surface conditions, will be needed to elucidate these considerations.
The eŠects of chitosan concentration on the particle size, yield, recovery and loading are shown in Fig.  2 . As chitosan concentration increased, the amount of the product rose, but LF-FTC recovery and loading fell. Figure 3 is the proposed scheme of the formation of Al/Ca-MP and Ch/Al/Ca-MP. Namely, as discussed above, the materials were highly recovered in the preparation of Al/Ca-MP by the emulsiˆcation-evaporation method. However, in chitosan coating with chitosan solution, surplus CaCl 2 in Al/ Ca-MP was considered to be lost by the dissolution, and chitosan could form a complex with alginate and remove LF-FTC from Al/Ca-MP to some extent due to its cationic charge. These were conˆrmed by the recovered amount and LF-FTC content and particle size ( Table 2 , Fig. 2 ). In Vitro Release As stated above, Al/Ca-MP was suspended in JP15 1st ‰uid, but the precipitate obtained by centrifugation of the Al/Ca-MP suspension dissolved easily in JP15 2nd ‰uid. Therefore, Al/ Ca-MP could not be used as controlled release microparticles. On the other hand, Ch/Al/Ca-MP hardly dissolved in JP15 1st or 2nd ‰uids. Therefore, Ch / Al / Ca-MP were considered adequate as microparticles physically durable in the stomach and intestine. The in vitro release proˆles of Ch/Al/Ca-MP in JP15 1st and 2nd ‰uids are shown in Fig. 4 . LF-FTC was released gradually from all Ch/Al/Ca-MP at both pH 1.2 and 6.8. The release rate became slower with the decrease of chitosan concentration. Ch0.25/Al/Ca-MP released LF-FTC at 39％ and 30 ％ in JP15 1st and 2nd ‰uids, respectively, at 7 h. Ch0.5/Al/Ca-MP released 43％ and 41％ of LF-FTC in JP15 1st and 2nd ‰uids, respectively, at 7 h. For Ch1.0/Al/Ca-MP, 79％ and 53％ of LF-FTC were released in JP15 1st and 2nd ‰uids, respectively, at 7 h. The initial release was greater in JP15 1st ‰uid than in JP15 2nd ‰uid for each kind of microparticle. A sequential release test using JP15 1st ‰uid, followed by JP15 2nd ‰uid, was performed. The release pattern was obtained as described in Fig. 5 . The release pro- le was almost consistent with the proˆle expected from the results obtained by examination with JP15 1st and 2nd ‰uids separately (Fig. 4) . These results suggested that Ch0.25/Al/Ca-MP and Ch0.5/Al/Ca-MP should be useful for sustained release. On the other hand, for Ch1.0/Al/Ca-MP, the initial release in JP15 1st ‰uid was too high to achieve a gradual release. At pH 1.2, chitosan and LF-FTC are highly ionized, while alginate is less ionized. LF-FTC, especially that located at the outer part, was considered to be released due to the hydration of chitosan and LF-FTC itself, ionic repulsion by chitosan and less interaction with alginate. These phenomena were considered to be caused more markedly in Ch/Al/Ca-MP with more chitosan like Ch1.0/Al/Ca-MP, resulting in a larger initial rapid release. As the pKa of amino groups of chitosan is approximately 6.3 7, 26) chitosan is partially cationized at pH 6.8, while alginate is highly anionized at this pH. Therefore, the hydration was considered to be caused throughout the particles at pH 6.8, leading to the gradual release of LF-FTC, but the release of LF-FTC located at the outer area might be suppressed due to incomplete ionization of chitosan, which also would be related to the retention of the ionic interaction between LF-FTC and alginate.
Physical States at Gastric and Intestinal pH SEM images in Fig. 5 show the shape of residues obtained after the sequential release test. Since Ch/Al/ Ca-MP were swollen and softened during incubation in JP15 2nd ‰uid, they were considered to be aggregated or entangled, resulting in the formation of a larger solid after the lyophilization. Particle states with the incubation of Ch0.5/Al/ Ca-MP in JP15 1st and 2nd ‰uids were observed by optical and ‰uorescence microscopy. In JP15 1st ‰uid, Ch0.5/Al/Ca-MP were not swollen or softened, that is, the core part was hard, resulting in clear ‰uorescence images (Fig. 6) . In JP15 2nd ‰uid, LF-FTC, released to a certain extent, was observed as solution ‰uorescence and, at this time, microparticles were observed without being dissolved. For Al/Ca-MP, disintegration and dissolution were observed.
Thus, Ch/Al/Ca-MP were shown to be durable microparticles under both gastric and intestinal pH conditions. Given their release, Ch0.25/Al/-MP and Ch0.5/Al/Ca-MP were proposed to act as smaller microparticles providing the prolonged supply of LF in the gastrointestinal tract. In the next study, it will be attempted for the purpose of practical application to scale up the production of microparticles and to incorporate LF at a higher ratio.
